There is growing interest in the use of bone marrow derived stem cells for bone repair. Increasing evidence now indicates that physiological bone remodelling occurs in close proximity to blood vessels and that these vessels carry perivascular stem cells that differentiate into osteoblasts. Non-union of bones are serious complication, incidences of which can be as high as 5% to 20%, varies by fracture site and is influenced by a number of fracture characteristics and host factors. The healing of fractures is a complex physiological process which could be interrupted by various factors. Thus, development of a novel therapeutic method to treat non-union fractures' becomes a clinical necessity. The purpose of this study was to assess the safety and efficacy of the autologous bone marrow concentrate preconditioned with synthetic graft in the treatment of non-union bone fractures. Autologous Bone Marrow Concentrate (aBMC) was prepared from bone marrow aspirate utilizing rapid, intraoperative point-of-care system via a density gradient centrifugation. A total of 17 patients were treated with aBMC at the fracture site and evaluated for the length of bone fracture healing time during the study follow-up period. The mean Total Nucleated Cell Count (TNCC) and Mononuclear Cell Count (MNCC) in all the patients were 5.54 x 10 8 ± 1.99 and 1.64 x 10 8 ± 0.86, respectively. 82% of the patients showed considerable bone healing of the non-union and the mean time for bone union/healing was 6 months. Overall the study concludes aBMC administration to be safe and effective in treating patients with atrophic non-unions and may contribute as an alternative to autologous cancellous bone graft.